For the year ending 2025-12-31, ABUS made $14,083K in revenue. -$33,464K in net income. Net profit margin of -237.62%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Revenue | 14,083 | 6,171 | ||
| Research and development | 25,241 | 54,037 | ||
| General and administrative | 15,893 | 22,108 | ||
| Change in fair value of contingent consideration | -1,830 | 2,625 | ||
| Restructuring costs | 12,939 | 3,720 | ||
| Total operating expenses | 52,243 | 82,490 | ||
| Loss from operations | -38,160 | -76,319 | ||
| Interest income | 4,068 | 6,585 | ||
| Gain on sale of property and equipment | 674 | - | ||
| Interest expense | 97 | 137 | ||
| Foreign exchange gain / (loss) | 14 | -49 | ||
| Total other income | 4,659 | 6,399 | ||
| Loss before income taxes | - | -69,920 | ||
| Income tax expense | - | 0 | ||
| Net loss | -33,501 | -69,920 | ||
| Unrealized gain on available-for-sale securities | 37 | 286 | ||
| Comprehensive loss | -33,464 | -69,634 | ||
| Basic EPS | -0.17 | -0.38 | ||
| Diluted EPS | -0.17 | -0.38 | ||
| Basic Average Shares | 191,599,600 | 185,608,874 | ||
| Diluted Average Shares | 191,599,600 | 185,608,874 | ||
Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp (ABUS)